Telbivudine is a b-L-thymidine nucleoside analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection. It is the fourth nucleoside or nucleotide analog to be marketed for this indication. The previous drugs from this class include lamivudine, a deoxythiacytosine analog, adefovir, a nucleotide analog, and entecavir, a guanosine analog. Adefovir, entecavir, and telbivudine are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections. Telbivudine is efficiently phosphorylated by cellular kinases to the active triphosphate derivative, which inhibits HBV DNA polymerase by competing with the natural substrate, thymidine- 5’-triphosphate.
| Product Name: | 2'-Deoxy-L-thymidine |
| Synonyms: | BETA-L-THYMIDINE;2'-DEOXY-L-THYMIDINE;L-Thymidine(Telbivudine);1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione;Β-L-2'-DEOXY-THYMIDINE;2'-Deoxy-L-thyMidine(Telbivudine);Telbivudine(Tyzeka, Sebivo);1-(2-Deoxy-β-L-erythro-pentofuranosyl)-5-Methyl- |
| CAS: | 3424-98-4 |
| MF: | C10H14N2O5 |
| MW: | 242.23 |
| EINECS: | 608-961-3 |
| Product Categories: | Anti-virals;Bases & Related Reagents;Carbohydrates & Derivatives;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;API intermediates;Amines;API;Chiral Reagents;Heterocycles |
| Mol File: | 3424-98-4.mol |
 |
Japan
